These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 27830425)

  • 1. Effects of an Unlabeled Loading Dose on Tumor-Specific Uptake of a Fluorescently Labeled Antibody for Optical Surgical Navigation.
    Moore LS; Rosenthal EL; de Boer E; Prince AC; Patel N; Richman JM; Morlandt AB; Carroll WR; Zinn KR; Warram JM
    Mol Imaging Biol; 2017 Aug; 19(4):610-616. PubMed ID: 27830425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma.
    Day KE; Sweeny L; Kulbersh B; Zinn KR; Rosenthal EL
    Mol Imaging Biol; 2013 Dec; 15(6):722-9. PubMed ID: 23715932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal Dosing Strategy for Fluorescence-Guided Surgery with Panitumumab-IRDye800CW in Head and Neck Cancer.
    Nishio N; van den Berg NS; van Keulen S; Martin BA; Fakurnejad S; Zhou Q; Lu G; Chirita SU; Kaplan MJ; Divi V; Colevas AD; Rosenthal EL
    Mol Imaging Biol; 2020 Feb; 22(1):156-164. PubMed ID: 31054001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800.
    Miller SE; Tummers WS; Teraphongphom N; van den Berg NS; Hasan A; Ertsey RD; Nagpal S; Recht LD; Plowey ED; Vogel H; Harsh GR; Grant GA; Li GH; Rosenthal EL
    J Neurooncol; 2018 Aug; 139(1):135-143. PubMed ID: 29623552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-Specific Fluorescent Labeling of Antibodies and Diabodies Using SpyTag/SpyCatcher System for In Vivo Optical Imaging.
    Alam MK; El-Sayed A; Barreto K; Bernhard W; Fonge H; Geyer CR
    Mol Imaging Biol; 2019 Feb; 21(1):54-66. PubMed ID: 29948640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer.
    Rosenthal EL; Warram JM; de Boer E; Chung TK; Korb ML; Brandwein-Gensler M; Strong TV; Schmalbach CE; Morlandt AB; Agarwal G; Hartman YE; Carroll WR; Richman JS; Clemons LK; Nabell LM; Zinn KR
    Clin Cancer Res; 2015 Aug; 21(16):3658-66. PubMed ID: 25904751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of fluorescence-guided surgery agents in a murine model of soft tissue fibrosarcoma.
    Prince AC; McGee AS; Siegel H; Rosenthal EL; Behnke NK; Warram JM
    J Surg Oncol; 2018 May; 117(6):1179-1187. PubMed ID: 29284070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterizing the detection threshold for optical imaging in surgical oncology.
    Prince AC; Jani A; Korb M; Tipirneni KE; Kasten BB; Rosenthal EL; Warram JM
    J Surg Oncol; 2017 Dec; 116(7):898-906. PubMed ID: 28628728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers.
    Gao RW; Teraphongphom N; de Boer E; van den Berg NS; Divi V; Kaplan MJ; Oberhelman NJ; Hong SS; Capes E; Colevas AD; Warram JM; Rosenthal EL
    Theranostics; 2018; 8(9):2488-2495. PubMed ID: 29721094
    [No Abstract]   [Full Text] [Related]  

  • 10. Preclinical evaluation of near-infrared (NIR) fluorescently labeled cetuximab as a potential tool for fluorescence-guided surgery.
    Saccomano M; Dullin C; Alves F; Napp J
    Int J Cancer; 2016 Nov; 139(10):2277-89. PubMed ID: 27428782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: A quantitative dose-escalation study.
    Voskuil FJ; de Jongh SJ; Hooghiemstra WTR; Linssen MD; Steinkamp PJ; de Visscher SAHJ; Schepman KP; Elias SG; Meersma GJ; Jonker PKC; Doff JJ; Jorritsma-Smit A; Nagengast WB; van der Vegt B; Robinson DJ; van Dam GM; Witjes MJH
    Theranostics; 2020; 10(9):3994-4005. PubMed ID: 32226534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging.
    Hekman MCH; Boerman OC; Bos DL; Massuger LFAG; Weil S; Grasso L; Rybinski KA; Oosterwijk E; Mulders PFA; Rijpkema M
    Mol Pharm; 2017 Oct; 14(10):3457-3463. PubMed ID: 28826214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescence Lifetime-Based Tumor Contrast Enhancement Using an EGFR Antibody-Labeled Near-Infrared Fluorophore.
    Pal R; Kang H; Choi HS; Kumar ATN
    Clin Cancer Res; 2019 Nov; 25(22):6653-6661. PubMed ID: 31481509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas.
    de Boer E; Warram JM; Tucker MD; Hartman YE; Moore LS; de Jong JS; Chung TK; Korb ML; Zinn KR; van Dam GM; Rosenthal EL; Brandwein-Gensler MS
    Sci Rep; 2015 Jun; 5():10169. PubMed ID: 26120042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorescently Labeled Cetuximab-IRDye800 for Guided Surgical Excision of Ameloblastoma: A Proof of Principle Study.
    Morlandt AB; Moore LS; Johnson AO; Smith CM; Stevens TM; Warram JM; MacDougall M; Rosenthal EL; Amm HM
    J Oral Maxillofac Surg; 2020 Oct; 78(10):1736-1747. PubMed ID: 32554066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a Centyrin-Based Near-Infrared Probe for Fluorescence-Guided Surgery of Epidermal Growth Factor Receptor Positive Tumors.
    Mahalingam SM; Dudkin VY; Goldberg S; Klein D; Yi F; Singhal S; O'Neil KT; Low PS
    Bioconjug Chem; 2017 Nov; 28(11):2865-2873. PubMed ID: 28945346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.
    Lütje S; Rijpkema M; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
    J Nucl Med; 2014 Jun; 55(6):995-1001. PubMed ID: 24700882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.
    Muselaers CH; Stillebroer AB; Rijpkema M; Franssen GM; Oosterwijk E; Mulders PF; Oyen WJ; Boerman OC
    J Nucl Med; 2014 Jun; 55(6):1035-40. PubMed ID: 24752673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model.
    Du Y; Sun T; Liang X; Li Y; Jin Z; Xue H; Wan Y; Tian J
    Int J Nanomedicine; 2017; 12():8337-8351. PubMed ID: 29200846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radionuclide and Fluorescence Imaging of Clear Cell Renal Cell Carcinoma Using Dual Labeled Anti-Carbonic Anhydrase IX Antibody G250.
    Muselaers CH; Rijpkema M; Bos DL; Langenhuijsen JF; Oyen WJ; Mulders PF; Oosterwijk E; Boerman OC
    J Urol; 2015 Aug; 194(2):532-8. PubMed ID: 25686542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.